EE512 Fluticasone Furoate/Umeclidinium/Vilanterol Vs Open Triple Therapy for Treating Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) from a Brazilian Public Healthcare Perspective: A Budget Impact Analysis
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2276
https://www.valueinhealthjournal.com/article/S1098-3015(24)02490-2/fulltext
Title :
EE512 Fluticasone Furoate/Umeclidinium/Vilanterol Vs Open Triple Therapy for Treating Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) from a Brazilian Public Healthcare Perspective: A Budget Impact Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02490-2&doi=10.1016/j.jval.2024.03.2276
First page :
Section Title :
Open access? :
No
Section Order :
10271